What is the price target for CORT stock?
12 analysts have analysed CORT and the average price target is 68.75 USD. This implies a price increase of 47.46% is expected in the next year compared to the current price of 46.62.
CORCEPT THERAPEUTICS INC (CORT) Forecast, Price Target & Analyst Ratings
NASDAQ:CORT • US2183521028
Current stock price
46.62 USD
+0.4 (+0.87%)
At close:
47.62 USD
+1 (+2.15%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CORCEPT THERAPEUTICS INC (CORT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
- 196.36M
Price Target Details & History
Consensus Price Target and Range
Mean target
$68.75
Upside
+ 47.46%
From current price of $46.62 to mean target of $68.75, Based on 12 analyst forecasts
Low
$44.44
Median
$61.20
High
$115.50
Price Target Revisions
1 Month
-19.76%
3 Months
-25.93%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for CORT. The average price target is 68.75 USD. This implies a price increase of 47.46% is expected in the next year compared to the current price of 46.62.
The average price target has been revised downward by 25.93% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.33%
CORT was analyzed by 12 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CORT.
In the previous month the buy percentage consensus was at a similar level.
CORT was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | Wolfe Research | Upgrade | Underperform -> Peer Perform |
| 2026-03-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | UBS | Initiate | Neutral |
| 2025-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-18 | Wolfe Research | Initiate | Peer Perform |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-01 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-01 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-31 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
- 196.36M
- Revenue Q2Q
- 24.90%
- EPS Q2Q
- -110.80%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-8.11%
EPS (1 Month)
0.00%
EPS (3 Months)
79.07%
Next Earnings Summary
CORT is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.02 USD and the consensus revenue estimate is 196.36M USD.
The next earnings revenue estimate has been revised downward by 8.11% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 482.375M 20.02% | 675.04M 39.94% | 761.407M 12.79% | 960M 26.08% | 1.219B 26.98% | 1.465B 20.18% | 1.759B 20.07% | 2.057B 16.94% | 2.465B 19.83% | 2.646B 7.34% | 2.756B 4.16% | |
| EBITDA YoY % growth | 108.324M -4.48% | 137.746M 27.16% | 45.946M -66.64% | 87.434M 90.30% | 170.69M 95.22% | 287.77M 68.59% | 413.41M 43.66% | 460.63M 11.42% | N/A | N/A | N/A | |
| EBIT YoY % growth | 107.282M -4.72% | 136.951M 27.66% | 44.797M -67.29% | 68.946M 53.91% | 393.7M 471.03% | 552.32M 40.29% | 956.19M 73.12% | 1.329B 38.99% | 1.564B 17.68% | 1.692B 8.18% | 1.762B 4.14% | |
| Operating Margin | 22.24% | 20.29% | 5.88% | 7.18% | 32.30% | 37.70% | 54.36% | 64.61% | 63.45% | 63.95% | 63.93% | |
| EPS YoY % growth | 0.95 7.95% | 1.24 30.53% | 0.82 -33.87% | 0.54 -33.82% | 1.45 166.60% | 3.13 116.63% | 6.25 99.51% | 8.57 37.08% | 9.68 12.93% | 10.45 7.96% | 10.86 3.95% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 -110.80% | 0.18 -36.69% | 0.16 0.72% | 0.29 43.82% | -0.01 44.44% | 0.27 44.44% | 0.37 127.85% | 0.42 47.16% |
| Revenue Q2Q % growth | 196.36M 24.90% | 230.69M 18.65% | 249.54M 20.18% | 283.41M 40.22% | 232.78M 18.55% | 280.71M 21.68% | 299.83M 20.15% | 317.94M 12.18% |
| EBITDA Q2Q % growth | 31.273M 744.99% | 32.722M 20.10% | 35.557M 220.94% | 41.514M 636.59% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.699M -354.64% | 5.922M -77.80% | 21.592M 111.29% | 45.444M 912.79% | 26.52M 404.88% | 49.368M 733.64% | 76.806M 255.72% | 101.39M 123.11% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
56.35%
EPS Next 5 Year
59.90%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
20.83%
Revenue Next 5 Year
19.89%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
47.49%
EBIT Next 5 Year
38.71%
CORCEPT THERAPEUTICS INC / CORT Forecast FAQ
When does CORCEPT THERAPEUTICS INC (CORT) report earnings?
CORCEPT THERAPEUTICS INC (CORT) will report earnings on 2026-04-30.
What are the consensus estimates for CORT stock next earnings?
The consensus EPS estimate for the next earnings of CORCEPT THERAPEUTICS INC (CORT) is -0.02 USD and the consensus revenue estimate is 196.36M USD.
Can you provide the consensus rating for CORCEPT THERAPEUTICS INC stock?
The consensus rating for CORCEPT THERAPEUTICS INC (CORT) is 78.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.